Search

Your search keyword '"Pisano, Carmela"' showing total 18 results
Start Over Author "Pisano, Carmela" Publication Year Range This year
18 results on '"Pisano, Carmela"'

2. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

Author

Monk, Bradley J., Romero, Ignacio, Graybill, Whitney, Churruca, Cristina, O'Malley, David M., Knudsen, Anja Ør, Yap, Oi Wah Stephanie, Baurain, Jean-François, Rose, Peter G., Denys, Hannelore, Ghamande, Sharad, Pisano, Carmela, Fabbro, Michel, Braicu, Elena Ioana, Calvert, Paula M., Amit, Amnon, Prendergast, Emily, Taylor, Adekemi, Kheibarshekan, Leila, Zhang, Zhi-Yi, Zajic, Stefan, Jewell, Roxanne C., Gupta, Divya, and González-Martín, Antonio

Published
2024
Full Text
View/download PDF

3. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial

Author

Roma, Cristin, Esposito Abate, Riziero, Sacco, Alessandra, Califano, Daniela, Arenare, Laura, Bergantino, Francesca, Pisano, Carmela, Cecere, Sabrina Chiara, Scambia, Giovanni, Lorusso, Domenica, Artioli, Grazia, Tasca, Giulia, Spina, Anna, Russo, Daniela, Gadducci, Angiolo, De Angelis, Carmine, Bologna, Alessandra, Marchini, Sergio, Capoluongo, Ettore Domenico, Perrone, Francesco, Pignata, Sandro, and Normanno, Nicola

Published
2024
Full Text
View/download PDF

4. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Author

Makker, Vicky, Perez-Fidalgo, Jose Alejandro, Valabrega, Giorgio, Hamilton, Erika, Van Gorp, Toon, Sehouli, Jalid, Regináčová, Klaudia, Richardson, Debra L., Perri, Tamar, Oza, Amit M., Miller, David S., Alía, Eva Maria Guerra, De Giorgi, Ugo, Henry, Stephanie, Spitz, Daniel L., Wimberger, Pauline, Bednaříková, Markéta, Chon, Hye Sook, Martínez-Garcia, Jerónimo, Pisano, Carmela, Berek, Jonathan S., Romero, Ignacio, Scambia, Giovanni, Fariñas-Madrid, Lorena, Buscema, Joseph, Schochter, Fabienne, Li, Kai, Kalyanapu, Pratheek, Walker, Christopher J., and Vergote, Ignace

Published
2024
Full Text
View/download PDF

5. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study

Author

Tuninetti, Valentina, Virano, Elisa, Salutari, Vanda, Ricotti, Andrea, Pisano, Carmela, Ducceschi, Monika, Turitto, Giacinto, Scandurra, Giuseppa, Petrella, Maria Cristina, Forestieri, Valeria, Rizzetto, Monica, Mammoliti, Serafina, Artioli, Grazia, Cioffi, Raffaella, Borsotti, Lucia, Bellero, Marco, Rognone, Chiara, Carbone, Vittoria, Ferrandina, Gabriella, Mantiero, Mara, Azzolina, Carmen, Geninatti, Eleonora, Pignata, Sandro, and Valabrega, Giorgio

Published
2024
Full Text
View/download PDF

6. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Pothuri, Bhavana, Han, Sileny, Chase, Dana M., Heitz, Florian, Burger, Robert A., Gaba, Lydia, Van Le, Linda, Guerra, Eva, Bender, David, Korach, Jacob, Cloven, Noelle, Churruca, Cristina, Follana, Philippe, DiSilvestro, Paul, Baurain, Jean-François, Jardon, Kris, Pisano, Carmela, Peen, Ulla, Mäenpää, Johanna, Gupta, Divya, Bacqué, Emeline, Li, Yong, Compton, Natalie, Antonova, Jenya, Monk, Bradley J., and González-Martín, Antonio

Published
2024
Full Text
View/download PDF

7. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

8. Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial.

Author

Indraccolo, Stefano, Signoriello, Simona, Piga, Ilaria, Esposito, Giovanni, Ferrarini, Federica, Boscolo Bragadin, Andrea, Salutari, Vanda, Pisano, Carmela, Califano, Daniela, Bignotti, Eliana, Tognon, Germana, Simeon, Vittorio, Artioli, Grazia, Ferrero, Annamaria, Cinieri, Saverio, Bologna, Alessandra, Chiodini, Paolo, Scognamiglio, Giosuè, Bottoni, Carolina, and Spina, Anna

Published
2024
Full Text
View/download PDF

9. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations

Author

Schouten, Philip C., primary, Schmidt, Sandra, additional, Becker, Kerstin, additional, Thiele, Holger, additional, Nürnberg, Peter, additional, Richters, Lisa, additional, Ernst, Corinna, additional, Treilleux, Isabelle, additional, Medioni, Jacques, additional, Heitz, Florian, additional, Pisano, Carmela, additional, Garcia, Yolanda, additional, Petru, Edgar, additional, Hietanen, Sakari, additional, Colombo, Nicoletta, additional, Vergote, Ignace, additional, Nagao, Shoji, additional, Linn, Sabine C., additional, Pujade-Lauraine, Eric, additional, Ray-Coquard, Isabelle, additional, Harter, Philipp, additional, Hahnen, Eric, additional, and Schmutzler, Rita K., additional

Published
2024
Full Text
View/download PDF

10. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma with BRCA -Like Genomic Aberrations

Author

Medisch Oncologische Disciplines, Pathologie, Cancer, Schouten, Philip C., Schmidt, Sandra, Becker, Kerstin, Thiele, Holger, Nürnberg, Peter, Richters, Lisa, Ernst, Corinna, Treilleux, Isabelle, Medioni, Jacques, Heitz, Florian, Pisano, Carmela, Garcia, Yolanda, Petru, Edgar, Hietanen, Sakari, Colombo, Nicoletta, Vergote, Ignace, Nagao, Shoji, Linn, Sabine C., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Harter, Philipp, Hahnen, Eric, Schmutzler, Rita K., Medisch Oncologische Disciplines, Pathologie, Cancer, Schouten, Philip C., Schmidt, Sandra, Becker, Kerstin, Thiele, Holger, Nürnberg, Peter, Richters, Lisa, Ernst, Corinna, Treilleux, Isabelle, Medioni, Jacques, Heitz, Florian, Pisano, Carmela, Garcia, Yolanda, Petru, Edgar, Hietanen, Sakari, Colombo, Nicoletta, Vergote, Ignace, Nagao, Shoji, Linn, Sabine C., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Harter, Philipp, Hahnen, Eric, and Schmutzler, Rita K.

Published
2024

11. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations

Author

Schouten, P, Schmidt, S, Becker, K, Thiele, H, Nürnberg, P, Richters, L, Ernst, C, Treilleux, I, Medioni, J, Heitz, F, Pisano, C, Garcia, Y, Petru, E, Hietanen, S, Colombo, N, Vergote, I, Nagao, S, Linn, S, Pujade-Lauraine, E, Ray-Coquard, I, Harter, P, Hahnen, E, Schmutzler, R, Schouten, Philip C, Schmidt, Sandra, Becker, Kerstin, Thiele, Holger, Nürnberg, Peter, Richters, Lisa, Ernst, Corinna, Treilleux, Isabelle, Medioni, Jacques, Heitz, Florian, Pisano, Carmela, Garcia, Yolanda, Petru, Edgar, Hietanen, Sakari, Colombo, Nicoletta, Vergote, Ignace, Nagao, Shoji, Linn, Sabine C, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Harter, Philipp, Hahnen, Eric, Schmutzler, Rita K, Schouten, P, Schmidt, S, Becker, K, Thiele, H, Nürnberg, P, Richters, L, Ernst, C, Treilleux, I, Medioni, J, Heitz, F, Pisano, C, Garcia, Y, Petru, E, Hietanen, S, Colombo, N, Vergote, I, Nagao, S, Linn, S, Pujade-Lauraine, E, Ray-Coquard, I, Harter, P, Hahnen, E, Schmutzler, R, Schouten, Philip C, Schmidt, Sandra, Becker, Kerstin, Thiele, Holger, Nürnberg, Peter, Richters, Lisa, Ernst, Corinna, Treilleux, Isabelle, Medioni, Jacques, Heitz, Florian, Pisano, Carmela, Garcia, Yolanda, Petru, Edgar, Hietanen, Sakari, Colombo, Nicoletta, Vergote, Ignace, Nagao, Shoji, Linn, Sabine C, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Harter, Philipp, Hahnen, Eric, and Schmutzler, Rita K

Abstract

Importance: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing. Objective: To investigate whether progression-free survival (PFS) and overall survival (OS) of patients with high-grade epithelial ovarian cancer treated with maintenance olaparib or placebo differed between patients with a tumor BRCA-like genomic profile and patients without a tumor BRCA-like profile. Design, Setting, and Participants: This cohort study was a secondary analysis of the PAOLA-1 randomized clinical trial that compared olaparib plus bevacizumab with placebo plus bevacizumab as maintenance treatment in patients with advanced high-grade ovarian cancer after a good response to first-line platinum with taxane chemotherapy plus bevacizumab, irrespective of germline or tumor BRCA1/2 mutation status. All patients with available tumor DNA were included in the analysis. The current analysis tested for an interaction between BRCA-like status and olaparib treatment on survival outcomes. The original trial was conducted between July 2015 and September 2017; at the time of data extraction for analysis in March 2022, a median follow-up of 54.1 months (IQR, 28.5-62.2 months) and a total follow-up time of 21711 months was available, with 336 PFS and 245 OS events. Exposures: Tumor homologous recombination deficiency was assessed using the BRCA-like copy number aberration profile classifier. Myriad MyChoice CDx was previously measured. The trial was randomized between the olaparib and bevacizumab and placebo plus bevacizumab groups. Main Outcomes and Measures: This secondary analysis assessed hazard ratios (HRs) of olaparib vs placebo among biomarker strata and tested for interaction between BRCA-like status and olaparib treatment on PFS and OS, using Cox proportional hazards regression. Results: A total of 469 patients (median age, 60 [range 26-80] years) were included in this study. T

Published
2024

12. Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

Author

Arezzo, Francesca, primary, Giannone, Gaia, additional, Castaldo, Daniele, additional, Scotto, Giulia, additional, Tuninetti, Valentina, additional, Turinetto, Margherita, additional, Bartoletti, Michele, additional, Mammoliti, Serafina, additional, Artioli, Grazia, additional, Mangili, Giorgia, additional, Salutari, Vanda, additional, Lorusso, Domenica, additional, Cormio, Gennaro, additional, Loizzi, Vera, additional, Zamagni, Claudio, additional, Savarese, Antonella, additional, Di Maio, Massimo, additional, Ronzino, Graziana, additional, Pisano, Carmela, additional, Pignata, Sandro, additional, and Valabrega, Giorgio, additional

Published
2024
Full Text
View/download PDF

13. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Mirza, Mansoor R, primary, González-Martín, Antonio, additional, Graybill, Whitney S, additional, O'Malley, David M, additional, Gaba, Lydia, additional, Stephanie Yap, Oi Wah, additional, Guerra, Eva M, additional, Rose, Peter G, additional, Baurain, Jean-François, additional, Ghamande, Sharad A, additional, Denys, Hannelore, additional, Prendergast, Emily, additional, Pisano, Carmela, additional, Follana, Philippe, additional, Baumann, Klaus, additional, Calvert, Paula M, additional, Korach, Jacob, additional, Li, Yong, additional, Malinowska, Izabela A, additional, Gupta, Divya, additional, and Monk, Bradley J, additional

Published
2024
Full Text
View/download PDF

14. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.

Author

Lorusso, Domenica, Raspagliesi, Francesco, Ronzulli, Dominique, Valabrega, Giorgio, Colombo, Nicoletta, Pisano, Carmela, Cassani, Chiara, Tognon, Germana, Tamberi, Stefano, Mangili, Giorgia, Mammoliti, Serafina, De Giorgi, Ugo, Greco, Filippo, Mosconi, Anna Maria, Breda, Enrico, Artioli, Grazia, Andreetta, Claudia, Casanova, Claudia, Ceccherini, Rita, and Frassoldati, Antonio

Published
2024
Full Text
View/download PDF

15. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Author

Lorusso, Domenica, Mouret-Reynier, Marie-Ange, Harter, Philipp, Cropet, Claire, Caballero, Cristina, Wolfrum-Ristau, Pia, Satoh, Toyomi, Vergote, Ignace, Parma, Gabriella, Nøttrup, Trine J., Lebreton, Coriolan, Fasching, Peter A., Pisano, Carmela, Manso, Luis, Bourgeois, Hugues, Runnebaum, Ingo, Zamagni, Claudio, Hardy-Bessard, Anne-Claire, Schnelzer, Andreas, and Fabbro, Michel

Published
2024
Full Text
View/download PDF

16. Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

Author

Arezzo, Francesca, Giannone, Gaia, Castaldo, Daniele, Scotto, Giulia, Tuninetti, Valentina, Turinetto, Margherita, Bartoletti, Michele, Mammoliti, Serafina, Artioli, Grazia, Mangili, Giorgia, Salutari, Vanda, Lorusso, Domenica, Cormio, Gennaro, Loizzi, Vera, Zamagni, Claudio, Savarese, Antonella, Di Maio, Massimo, Ronzino, Graziana, Pisano, Carmela, and Pignata, Sandro

Subjects
ENDOMETRIAL cancer, PHYSICIANS, IMMUNE checkpoint inhibitors, METASTASIS, OVARIAN cancer, THERAPEUTICS, IPILIMUMAB, PEMETREXED
Abstract

Introduction: Endometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%-15% of women with EC are diagnosed with advancedstage disease, resulting in a reported 5-year survival rate of only 17% for those with distant metastases. A better understanding of its molecular features has ushered in a new era of immunotherapy for the treatment of EC, allowing for alternative therapeutic approaches, even in cases of advanced disease. Methods: We administered a multi-choice online survey for Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) members. The questionnaire was available for 2 months, starting in October 2022. Our objective was to evaluate the current attitude of incorporating molecular characterization of EC into routine clinical practice, appraise the implementation of newly available therapies, and compare the outcomes with the previous survey conducted in April-May 2021 to ascertain the actual changes that have transpired during this recent time period. Results: The availability of molecular classification in Italian centers has changed in 1 year. Seventy-five percent of centers performed the molecular classification compared with 55.6% of the previous survey. Although this percentage has increased, only 18% performed all the tests. Significant changes have occurred in the administration of new treatments in EC patients in MITO centers. In 2022, 82.1% of the centers administrated dostarlimab in recurrent or advanced MMRdeficient (dMMR) EC experiencing disease progression after platinum-based chemotherapy regimens, compared to only 24.4% in 2021. In 2022, 85.7% of the centers already administrated the pembrolizumab plus lenvatinib combination as a second-line therapy for MMR-proficient (pMMR) patients with advanced or recurrent EC who had progressed from first-line platinumbased therapy. Conclusion: Both the therapeutic and diagnostic scenarios have changed over the last couple of years in MITO centers, with an increased prescription of immune checkpoint inhibitors and use of the molecular classification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

Author

Turinetto, Margherita, Ricotti, Andrea, Marchetti, Claudia, Pisano, Carmela, Zamagni, Claudio, Cassani, Chiara, Malaguti, Paola, Baldoni, Alessandra, Scollo, Paolo, Scandurra, Giuseppa, Parisi, Alessandro, Artioli, Grazia, Palaia, Innocenza, Vertechy, Laura, Bergamini, Alice, Picardo, Elisa, Tuninetti, Valentina, Scotto, Giulia, Scambia, Giovanni, and Pignata, Sandro

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, RESEARCH, DISEASE progression, HAND-foot syndrome, OVARIAN tumors, SCIENTIFIC observation, CONFIDENCE intervals, DOXORUBICIN, RESEARCH methodology, CASE-control method, RETROSPECTIVE studies, GASTROINTESTINAL diseases, PLATINUM, BLOOD diseases, DESCRIPTIVE statistics, RESEARCH funding, FATIGUE (Physiology), ENZYME inhibitors, EVALUATION
Abstract

Simple Summary: This multicenter, retrospective analysis had the objective of comparing the efficacy of PLD-Trabectedin in patients who had already been treated with PARP-I (cases) before vs. PARPi-naïve patients (controls). Data from 166 patients were collected, composed of 109 cases and 57 controls. In total, 135 patients were included in our analyses, composing 46 controls and 89 cases. We found a median PFS of 11 months (95% IC 10–12) in the control group vs. 8 months (95% IC 6–9) in the case group (p value 0.0017). The clinical benefit rate was evaluated, with an HR for progression of 2.55 (1.28–5.06) for the case group (p value 0.008) persisting when adjusted for BRCA mutation. The study showed a statistically significant difference in terms of PFS, suggesting that a previous exposure to PARP-i might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted. Objective: While PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, its efficacy and tolerability has so far not been tested extensively in patients who progress after poly ADP-ribose polymerase inhibitor (PARPi) treatment. Methodology: This multicenter, retrospective analysis had the objective of comparing patients receiving PLD-Trabectedin after being treated with PARP-I (cases) with PARPi-naïve patients. Descriptive and survival analyses were performed for each group. Results: Data from 166 patients were collected, composed of 109 cases and 57 controls. In total, 135 patients were included in our analyses, composing 46 controls and 89 cases. The median PFS was 11 months (95% IC 10–12) in the control group vs. 8 months (95% IC 6–9) in the case group (p value 0.0017). The clinical benefit rate was evaluated, with an HR for progression of 2.55 (1.28–5.06) for the case group (p value 0.008), persisting when adjusted for BRCA and line with treatment. We compared hematological toxicity, gastro-intestinal toxicity, hand–foot syndrome (HFS), fatigue, and liver toxicity, and no statistically significant disparity was noted, except for HFS with a p value of 0.006. The distribution of G3 and G4 toxicities was also equally represented. Conclusion: The MITO39 study showed a statistically significant difference in terms of PFS, suggesting that previous exposure to PARPi might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted; PLD-Trabectedin was confirmed to be a well-tolerated scheme in both groups. To our knowledge, these are the first data regarding this topic, which we deem to be of great relevance in the current landscape. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, and Yunokawa, Mayu

Abstract

The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results